Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

343

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions

Prepandemic Influenza Vaccine

Interventions

BIOLOGICAL

Monovalent inactivated influenza vaccine

2 doses of monovalent inactivated influenza vaccine with adjuvant

Trial Locations (2)

Pestlőrinc-Pestszentimre Egészségügyi Szolgáltató KFT, Budapest

Bács-Kiskun Megyei Kórház Tüdőgondozó Intézet, Kecskemét